The role of colchicine in the management of COVID-19: a Meta-analysis
Kholoud Elshiwy, Ghada Essam El-Din Amin, Mohamed Nazmy Farres, Rasha Samir, Mohamed Farouk Allam
BMC Pulmonary Medicine, doi:10.1186/s12890-024-03001-0
Background The Coronavirus disease 2019 (COVID-19) pandemic has robustly affected the global healthcare and economic systems and it was caused by coronavirus-2 (SARS-CoV-2). The clinical presentation of the disease ranges from a flu-like illness to severe pneumonia and death. Till September 2022, the cumulative number of cases exceeded 600 million worldwide and deaths were more than 6 million. Colchicine is an alkaloid drug that is used in many autoinflammatory conditions e.g., gout, familial Mediterranean fever, and Behçet's syndrome. Colchicine inhibits the production of superoxide and the release of interleukins that stimulate the inflammatory cascade. Colchicine decreases the differentiation of myofibroblast and the release of fibrotic mediators including transforming growth factor (TGF-β1) that are related to the fibrosis. Moreover, colchicine has been used to traet viral myocarditis caused by CMV or EBV, interstitial pneumonia, and pericarditis resulting from influenza B infection. Additionally, colchicine is considered safe and affordable with wide availability.
Objective The aim of the current study was to assess the evidence of colchicine effectiveness in COVID-19 treatment. Methods A comprehensive review of the literature was done till May 2022 and yielded 814 articles after ranking the articles according to authors and year of publication. Only 8 clinical trials and cohort studies fulfilling the inclusion criteria were included for further steps of data collection, analysis, and reporting.
Results This meta-analysis involved 16,488 patients; 8146 patients in the treatment group and 8342 patients in the control group. The results showed that colchicine resulted in a significant reduction in the mortality rate among patients received colchicine in comparison with placebo or standard care (RR 0.35, 95%CI: 0.15-0.79). Colchicine resulted in a significant decrease in the need for O2 therapy in patients with COVID-19 (RR 0.07, 95%CI 0.02-0.27, P = 0.000024). However, colchicine had no significant effect on the following outcomes among COVID-19 patients: the need for hospitalization, ICU admission, artificial ventilation, and hospital discharge rate. Among the PCR confirmed COVID-19 patients, colchicine decreased the hospitalization rate (RR 0.75, 95%CI 0.57-0.99, P = 0.042). However, colchicine had no effect on mortality and the need for mechanical ventilation among this subgroup.
Conclusion Colchicine caused a significant clinical improvement among COVID-19 patients as compared with the standard care or placebo, in terms of the need for O2, and mortality. This beneficial effect could play a role in the management of COVID-19 especially severe cases to decrease need for oxygen and to decrease mortality among these patients.
Authors' contributions Kholoud Elshiwy: Field work supervision, analysis strategy and design, data management, data analysis and interpretation of results, decision making on content and paper write-up and revision of final draft. Ghada Essam El-Din Amin: Field work supervision, analysis strategy and design, data management, data analysis and interpretation of results, decision making on content and paper write-up and revision of final draft. Mohamed Nazmy: Field work supervision, analysis strategy and design, data management, data analysis and
Declarations Ethics approval and consent to participate Not applicable.
Consent for publication Not applicable.
Competing interests The authors declare no competing interests.
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Bhattacharyya, Panda, Gupta, Anti-mitotic activity of colchicine and the structural basis for its interaction withTubulin, Med Res Rev
Bozkurt, Bicak, Sipahi, Taskin, Hur et al., The effects of colchicine on the progression and regression of encapsulating peritoneal sclerosis, Perit Dial Int
Brunetti, Diawara, Tsai, Colchicine to weather the cytokine storm in hospitalized patients with COVID-19, J Clin Med
Cronstein, Esserman, Sunkureddi, Mechanistic aspects of inflammation and clinical Management of Inflammation in acute gouty arthritis, J Clin Rheumatol
Deftereos, Giannopoulos, Vrachatis, Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial, JAMA Netw Open
Eikelboom, Jolly, Belley-Cote, Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial, Lancet Respir Med
Elshafei, El-Bardissy, Khalil, Colchicine use might be associated with lower mortality in COVID-19 patients: a meta-analysis, Eur J Clin Investig
Group, Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet Respir Med
Hageman, The coronavirus disease 2019 (COVID-19), Pediatr Ann
Han, Lin, You, Coronavirus 2019-nCoV: a brief perspective from the front line, J Infect
Hariyanto, Halim, Jodhinata, Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis, Clin Exp Pharmacol Physiol
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell
Klok, Kruip, Van Der Meer, Incidence of thrombotic complications in critically ill ICU patients with COVID-19, Thromb Res
Korkmaz, Erturan, Naziroǧlu, Colchicine modulates oxidative stress in serum and neutrophil of patients with Behçet disease through regulation of ca 2+ release and antioxidant system, J Membr Biol
Kow, Lee, Ramachandram, The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: a meta-analysis of randomized trials, Immun Inflamm Disease
Lho, Do, Heo, Kim, Kim et al., Effects of TGF-β1 Receptor Inhibitor GW788388 on the Epithelial to Mesenchymal Transition of Peritoneal Mesothelial Cells, Int J Mol Sci
Lopes, Bonjorno, Giannini, Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial, RMD Open
Lu, Zhao, Li, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet
Mareev, Orlova, Plisyk, Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study, Kardiologiya
Mehraeen, Salehi, Behnezhad, Moghaddam, Seyedalinaghi, Transmission modes of COVID-19: a systematic review, Infect Disord Drug Targets
Mehta, Patel, Chavda, Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials, RMD Open
Pandit, Matthews, A SARS-CoV-2: companion animal transmission and variants classification, Pathogens
Rahman, Early prediction and HRCT evaluation of post covid-19 related lung fibrosis, Microbiol Insights
Sandhu, Tieng, Chilimuri, Franchin, A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe covid-19 infection, Can J Infect Dis Med Microbiol
Sanghavi, Bansal, Kaur, Impact of colchicine on mortality and morbidity in COVID-19: a systematic review, Ann Med
Scarsi, Piantoni, Colombo, Association between treatment with colchicine and improved survival in a single-Centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome, Ann Rheum Dis
Schlesinger, Firestein, Brunetti, Colchicine in COVID-19: an old drug, New Use In Current Pharmacology Reports
Struyf, Deeks, Dinnes, Takwoingi, Davenport et al., Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19, Cochrane Database Syst Rev,
doi:10.1002/14651858.CD013665.pub3Tardif, Bouabdallaoui, Allier, Colchicine for communitytreated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial, Lancet Respir Med
Toro-Huamanchumo, Benites-Meza, Mamani-García, Efficacy of colchicine in the treatment of COVID-19 patients: a systematic review and Meta-analysis, J Clin Med
Van Doremalen, Bushmaker, Morris, Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1, N Engl J Med
Wu, Leung, Leung, Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study, Lancet
Xu, Shi, Wang, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med
Zein, Raffaello, Effect of colchicine on mortality in patients with COVID-19 -a systematic review and meta-analysis, Diabet Metabol Syndrome: Clin Res Rev
